ArticleMicrobiology spectrum2025
Berberine alleviates respiratory syncytial virus (RSV)-induced pediatric bronchiolitis and fibrosis via suppressing the HMGB1/TLR4/NF-κB pathway.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Programmed cell death in human respiratory syncytial virus infection.Frontiers in cellular and infection microbiology · 2025Pooled it
- Lactobacillus Plantarum R-Fermented Phellodendron Amurense Extract Protects Against Pseudorabies Virus by Regulating Oxidative Stress and Inflammation in Vitro and in Vivo.Probiotics and antimicrobial proteins · 2026Article
- Screening of key host targets and mechanistic assessment of berberine modulation of host responses to respiratory syncytial virus.The Journal of international medical research · 2026Article
- Biosynthesis of benzylisoquinoline alkaloids and its evolution in plants.Plant communications · 2026Review
- Involvement of the pyroptosis-HMGB1 axis in systemic diseases.Frontiers in cell and developmental biology · 2026Review
- Pyroptosis in Respiratory Virus Infections: A Narrative Review of Mechanisms, Pathophysiology, and Potential Therapeutic Interventions.Microorganisms · 2025Review
- Multimodal cell death drives the immunopathogenesis of RSV infection.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Berberine exhibits antitumor, antibacterial, and antiviral properties. This study explored its therapeutic potential and molecular mechanism in respiratory syncytial virus (RSV)-induced pediatric bronchiolitis (PB). BEAS-2B cells were infected with RSV (multiplicity of infection = 0.5, 1.0, or 5.0) to establish a PB cell model. Quantitative reverse transcription PCR (qRT-PCR) quantified RSV, HMGB1, and fibrosis-related genes. MTT assay assessed cell viability, and plaque assay measured RSV titers. Western blot, immunohistochemistry (IHC), immunofluorescence, and enzyme-linked immunosorbent assay (ELISA) evaluated HMGB1 and key markers of inflammation, pyroptosis, epithelial-mesenchymal transition (EMT), and fibrosis. Flow cytometry analyzed apoptosis, while electron microscopy visualized RSV-induced pyroptotic and apoptotic changes. A PB mouse model was established by administering RSV (6.8 × 10⁶ PFU) via nasal drip in BALB/c mice. Mice were divided into six groups ( IMPORTANCE: Pediatric bronchiolitis caused by RSV remains a major global health challenge with limited treatment options. This study highlights berberine as a promising therapeutic agent capable of reducing RSV replication and associated lung injury. By targeting the HMGB1/TLR4/NF-κB pathway, berberine effectively attenuates inflammation, pyroptosis, EMT, and fibrosis. These findings provide a novel mechanistic insight and offer potential for the development of targeted therapies against RSV-induced bronchiolitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.